The focus of the industry on human living organisms and highly controlled www.genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ standards make it a unique challenge for business leaders. These aspects make the sector an ideal incubator for innovation. They have resulted in major breakthroughs in the production of biofuels and agricultural yields and life-saving pharmaceuticals.

Start-up biotech companies have many options when it comes down to revenue generation strategies, with the majority opting for a technology-based partnership or an out-licensing and asset creation strategy. Technology partnering can bring higher revenue and lower financial risk, while strategies for asset creation and outlicensing can yield greater returns. A growing number of biotechs in the research stage operate an hybrid model that blends both approaches.

Those who choose a product-oriented strategy are more likely to achieve commercial success as long as they are able to bring their pipelines up to the right stage, and also find a significant pharmaceutical partner or investor with a deep pocket. This can be an expensive investment. It is important to balance opportunistic approaches in leveraging outside assets and the best scientific decisions for home-grown projects.

Another option is the “platform” model provides an alternative path to revenue. It’s a cheaper option than the product-oriented development but it comes with substantial risks. In this model biotechs own and develops its platform technology before working with large pharma companies to develop a portfolio of drug discovery projects that focus on specific disease areas (i.e. disease x in biology y). This is the method Advinus Therapeutics and a few others have adopted.